AtaiBeckley Inc. Common Stock (ATAI) Stock
NASDAQ · ATAI
7.35
Fundamentals
Market cap
$2.73B
Price / Earnings ratio
0.0x
Price / Sales ratio
609.4x
Price / Book ratio
15.5x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
N/A
Dividend yield
91.84%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
NeutralATAISeptember 10, 2026
Zacks Investment ResearchNeutral
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
ATAI

Zacks Investment Research
Lilly Builds Neuroscience into a New Long-Term Growth Driver
NeutralATAISeptember 8, 2026
Zacks Investment ResearchNeutral
Lilly Builds Neuroscience into a New Long-Term Growth Driver
ATAI

Business Wire
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
NeutralATAIAugust 17, 2026
Business WireNeutral
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
ATAI

Zacks Investment Research
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
NeutralATAIAugust 7, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
ATAI
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral9
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
5M3M2M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
351M232M116M0
Revenue to Profit
2025$4.1M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-660.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
NeutralATAISeptember 10, 2026
Zacks Investment ResearchNeutral
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
ATAI

Zacks Investment Research
Lilly Builds Neuroscience into a New Long-Term Growth Driver
NeutralATAISeptember 8, 2026
Zacks Investment ResearchNeutral
Lilly Builds Neuroscience into a New Long-Term Growth Driver
ATAI

Business Wire
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
NeutralATAIAugust 17, 2026
Business WireNeutral
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
ATAI

Zacks Investment Research
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
NeutralATAIAugust 7, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
ATAI

The Motley Fool
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
NeutralATAIJuly 29, 2026
The Motley FoolNeutral
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
ATAI

Stocktwits
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
NeutralATAIJuly 23, 2026
StocktwitsNeutral
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
ATAI

Zacks Investment Research
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
NeutralATAIJuly 22, 2026
Zacks Investment ResearchNeutral
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
ATAI

Stocktwits
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
NeutralATAIJuly 20, 2026
StocktwitsNeutral
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
ATAI

Stocktwits
Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?
NeutralATAIJuly 20, 2026
StocktwitsNeutral
Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week?
ATAI

CNBC
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
NeutralATAIJuly 19, 2026
CNBCNeutral
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
ATAI
About AtaiBeckley Inc. Common Stock
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
SectorHealthcare
IndustryBiotechnology
Employees99
IPO DateJun 16, 2021
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Glenn Short Ph.D. | Chief Scientific Officer | 1970 |
| Dr. Jason Awe Ph.D. | Vice President of Investor Relations | — |
Fundamentals
Valuation
Market cap$2.73B
Price-to-sales ratio609.41
Price-to-book value15.46
Price-earnings ratio0.00
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.77
Income Statement
Average volume12,883,632
EBITDA$-661.66M
1 year high (52w)$7.45
1 year low (52w)$3.27
Dividend
Ex dividend dateN/A
Dividend amountN/A
Dividend yield91.84%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
9 Wall Street Analyst Ratings
HOLD
0% Buy
100% Hold
0% Sell
Target price
$7.75
Est return
5.44%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.0 | +5.3 | -29.3 | -30.1 | ||||||||
| 2022 | -30.4 | +4.7 | -12.2 | -19.4 | -13.1 | -0.3 | +5.8 | +26.8 | -24.6 | -11.1 | +4.4 | -20.4 |
| 2023 | -32.8 | -8.7 | +12.4 | +0.5 | -9.6 | +0.0 | +10.6 | -25.4 | -16.2 | -0.8 | -12.6 | +25.9 |
| 2024 | +5.3 | +7.2 | -7.5 | +6.5 | -23.4 | -17.4 | +14.8 | -8.5 | -4.9 | -5.4 | +64.8 | -21.3 |
| 2025 | -3.1 | -7.0 | -9.3 | +21.0 | +57.1 | -12.0 | +51.3 | +9.8 | +15.3 | +12.3 | -27.3 | +6.5 |
| 2026 | -2.8 | -5.5 | -3.8 | +12.4 | +9.4 | +9.3 | +47.1 | +2.2 | +0.1 |



